Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University 2003 - 2004
  • Resident in Medicine, Medicine, Duke University 2000 - 2003
  • M.D., Thomas Jefferson University 2000
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2013
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007
  • Associate in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2004 - 2005
• Recognition
• 

  In the News

  • MAR 4, 2015

    Australian Broadcasting’s “Health Report”

    Dr. Richard Riedel: Early palliative care can cut hospital re-admissions for cancer patients

  • NOV 7, 2014

    Duke Chronicle

    Duke revolutionizes cancer care, garners national attention

  • OCT 22, 2014

    Early Palliative Care Can Cut Hospital Readmissions for Cancer Patients
• Research
• 

  Selected Grants

  • NIR-DT-301 -1702 2019 - 2024
  • DCC-2618-03-002 (Intrigue) 2019 - 2024
  • CL-PTL-130 2019 - 2023
  • IMDZ-04-1702 2018 - 2023
  • BLU-285-1303 2018 - 2023
  • TK216-01 2018 - 2023
  • NC-6300-001_Nanoparticle Epirubicin 2017 - 2022
  • STARTRK-2 2017 - 2022
  • SARC032 2017 - 2022
  • KCP-330-020 2016 - 2021
  • IMDZ-C232 2016 - 2021
  • A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewin 2014 - 2020
  • Lilly JGDJ 2015 - 2020
  • PEComa 2015 - 2020
  • A Phase IB Dose-Escalation Study of TRC105 in combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma 2013 - 2020
  • PLX108-10 2015 - 2020
  • SARC 028 2015 - 2020
  • ARO-012 (CrenoGIST) 2017 - 2019
  • SARC 024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas 2015 - 2018
  • Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics awarded by National Institutes of Health 2008 - 2013
• 

  Industry Relationships

  • AADI
  • AROG Pharmaceuticals
  • Blueprint Medicines
  • Copernicus Group Inc.
  • Daiichi Sankyo Co., Ltd
  • Deciphera
  • Eli Lilly & Co.
  • Ignyta
  • Immune Design
  • Karyopharm Therapeutics Inc
  • NanoCarrier
  • Oncternal
  • Springworks
  • Tracon
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Riedel, Richard, Sebastian Michels, Carina Heydt, Janna Siemanowski, Carsten Kobe, Anne Bunck, Stephan Schäfer, et al. “Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma..” Lung Cancer 133 (July 2019): 20–22. https://doi.org/10.1016/j.lungcan.2019.05.006.
       Full Text  Link to Item
    • Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant Chawla, Mark Agulnik, et al. “Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma..” J Clin Oncol 37, no. 16 (June 1, 2019): 1424–31. https://doi.org/10.1200/JCO.18.02374.
       Full Text  Link to Item
    • Ray, Emily M., Richard F. Riedel, Thomas W. LeBlanc, Christel N. Rushing, and Anthony N. Galanos. “Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment..” J Palliat Med 22, no. 4 (April 2019): 420–23. https://doi.org/10.1089/jpm.2018.0235.
       Full Text  Link to Item
    • Schwartz, Abby J., Richard F. Riedel, Thomas W. LeBlanc, Devi Desai, Carol Jenkins, Ellen Mahoney, Janice Humphreys, and Cristina C. Hendrix. “The experiences of older caregivers of cancer patients following hospital discharge..” Support Care Cancer 27, no. 2 (February 2019): 609–16. https://doi.org/10.1007/s00520-018-4355-2.
       Full Text  Link to Item
    • Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration..” The Lancet. Oncology 20, no. 1 (January 2019): 14–15. https://doi.org/10.1016/s1470-2045(18)30745-9.
       Full Text
    • Gounder, Mrinal M., Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, et al. “Sorafenib for Advanced and Refractory Desmoid Tumors..” The New England Journal of Medicine 379, no. 25 (December 2018): 2417–28. https://doi.org/10.1056/nejmoa1805052.
       Full Text
    • Riedel, Richard F., Robin L. Jones, Antoine Italiano, Chet Bohac, Juliette C. Thompson, Kerstin Mueller, Zaeem Khan, Seth M. Pollack, and Brian A. Van Tine. “Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review..” Cancers (Basel) 10, no. 11 (November 1, 2018). https://doi.org/10.3390/cancers10110417.
       Full Text  Link to Item
    • Wisdom, Amy J., Yvonne M. Mowery, Richard F. Riedel, and David G. Kirsch. “Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma..” Cancer 124, no. 19 (October 1, 2018): 3819–29. https://doi.org/10.1002/cncr.31517.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text  Link to Item
    • Mehren, Margaret von, R Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Kristen N. Ganjoo, Suzanne George, et al. “Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..” J Natl Compr Canc Netw 16, no. 5 (May 2018): 536–63. https://doi.org/10.6004/jnccn.2018.0025.
       Full Text  Link to Item
    • Choe, Jennifer, and Richard Riedel. “Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas..” F1000res 7 (2018). https://doi.org/10.12688/f1000research.15868.1.
       Full Text  Link to Item
    • Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, Canc Genome Atlas Res, and Canc Genome Atlas Res Cancer Genome Atlas Research Network. “Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas..” Cell 171, no. 4 (November 2, 2017): 950-965.e28. https://doi.org/10.1016/j.cell.2017.10.014.
       Full Text  Link to Item
    • Tawbi, Hussein A., Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra D’Angelo, et al. “Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial..” Lancet Oncol 18, no. 11 (November 2017): 1493–1501. https://doi.org/10.1016/S1470-2045(17)30624-1.
       Full Text  Link to Item
    • Riedel, Richard F., Kim Slusser, Steve Power, Christopher A. Jones, Thomas W. LeBlanc, Arif H. Kamal, Devi Desai, et al. “Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service..” J Oncol Pract 13, no. 9 (September 2017): e738–48. https://doi.org/10.1200/JOP.2017.022749.
       Full Text  Link to Item
    • Tap, William D., Zsuzsanna Papai, Brian A. Van Tine, Steven Attia, Kristen N. Ganjoo, Robin L. Jones, Scott Schuetze, et al. “Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial..” Lancet Oncol 18, no. 8 (August 2017): 1089–1103. https://doi.org/10.1016/S1470-2045(17)30381-9.
       Full Text  Link to Item
    • Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors..” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.
       Full Text  Link to Item
    • Wagner, Andrew J., Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret von Mehren, Jonathan Trent, et al. “Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour..” Eur J Cancer 61 (July 2016): 94–101. https://doi.org/10.1016/j.ejca.2016.03.076.
       Full Text  Link to Item
    • Mehren, Margaret von, R Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ernest U. Conrad, Kristen N. Ganjoo, et al. “Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology..” J Natl Compr Canc Netw 14, no. 6 (June 2016): 758–86. https://doi.org/10.6004/jnccn.2016.0078.
       Full Text  Link to Item
    • Whitley, Melodi Javid, Diana M. Cardona, Alexander L. Lazarides, Ivan Spasojevic, Jorge M. Ferrer, Joan Cahill, Chang-Lung Lee, et al. “A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer..” Sci Transl Med 8, no. 320 (January 6, 2016). https://doi.org/10.1126/scitranslmed.aad0293.
       Full Text  Link to Item
    • Hendrix, Cristina C., Donald E. Bailey, Karen E. Steinhauser, Maren K. Olsen, Karen M. Stechuchak, Sarah G. Lowman, Abby J. Schwartz, et al. “Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being..” Support Care Cancer 24, no. 1 (January 2016): 327–36. https://doi.org/10.1007/s00520-015-2797-3.
       Full Text  Link to Item
    • Gwin, W., and R. F. Riedel. “Chemotherapy in soft-tissue sarcoma: where do we go from here?.” Oncology (Williston Park, N.Y.) 29, no. 1 (January 1, 2015).
    • Gwin, W., and R. F. Riedel. “Chemotherapy in soft-tissue sarcoma: where do we go from here?.” Oncology (Williston Park, N.Y.) 29, no. 1 (January 1, 2015).
    • Gwin, William, and Richard F. Riedel. “Chemotherapy in soft-tissue sarcoma: where do we go from here?.” Oncology (Williston Park) 29, no. 1 (January 2015): 50–53.
       Link to Item
    • Jiang, Xiaoyin, H Bryan Anderson, Cynthia D. Guy, Paul J. Mosca, Richard F. Riedel, and Diana M. Cardona. “Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib..” Case Rep Oncol Med 2015 (2015). https://doi.org/10.1155/2015/317493.
       Full Text  Link to Item
    • Slusser, K., S. Power, C. A. Jones, T. W. LeBlanc, A. Kamal, D. Desai, D. Allen, and A. N. Galanos. “Early palliative care on an inpatient oncology unit: Impact of a novel co-rounding partnership on patient and health system outcomes..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 31_suppl (November 2014).
    • Mehren, Margaret von, R Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, et al. “Gastrointestinal stromal tumors, version 2.2014..” J Natl Compr Canc Netw 12, no. 6 (June 2014): 853–62. https://doi.org/10.6004/jnccn.2014.0080.
       Full Text  Link to Item
    • Mehren, Margaret von, R Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, et al. “Soft tissue sarcoma, version 2.2014..” J Natl Compr Canc Netw 12, no. 4 (April 2014): 473–83. https://doi.org/10.6004/jnccn.2014.0053.
       Full Text  Link to Item
    • Meadows, Kellen L., Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, and Herbert I. Hurwitz. “Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302..” Clinical Trials, November 2013. https://doi.org/10.1158/1535-7163.targ-13-c61.
       Full Text
    • Demetri, George D., Sant P. Chawla, Isabelle Ray-Coquard, Axel Le Cesne, Arthur P. Staddon, Mohammed M. Milhem, Nicolas Penel, et al. “Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy..” J Clin Oncol 31, no. 19 (July 1, 2013): 2485–92. https://doi.org/10.1200/JCO.2012.45.5766.
       Full Text  Link to Item
    • Larrier, Nicole A., David G. Kirsch, Richard F. Riedel, Howard Levinson, William C. Eward, and Brian E. Brigman. “Practical radiation oncology for extremity sarcomas..” Surg Oncol Clin N Am 22, no. 3 (July 2013): 433–43. https://doi.org/10.1016/j.soc.2013.02.004.
       Full Text  Link to Item
    • Cuneo, Kyle C., Richard F. Riedel, Leslie G. Dodd, David H. Harpole, and David G. Kirsch. “Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy..” J Clin Oncol 30, no. 28 (October 1, 2012): e291–93. https://doi.org/10.1200/JCO.2012.42.8797.
       Full Text  Link to Item
    • Mehren, Margaret von, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, Thomas F. DeLaney, Kristen N. Ganjoo, et al. “Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines..” J Natl Compr Canc Netw 10, no. 8 (August 2012): 951–60. https://doi.org/10.6004/jnccn.2012.0099.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors..” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
       Full Text  Link to Item
    • Riedel, Richard F., Alessandro Porrello, Emily Pontzer, Emily J. Chenette, David S. Hsu, Bala Balakumaran, Anil Potti, Joseph Nevins, and Phillip C. Febbo. “Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance..” Mol Cancer Ther 11, no. 5 (May 2012): 1214–15. https://doi.org/10.1158/1535-7163.MCT-12-0210.
       Full Text  Link to Item
    • Riedel, Richard F. “Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches..” Cancer 118, no. 6 (March 15, 2012): 1474–85. https://doi.org/10.1002/cncr.26415.
       Full Text  Link to Item
    • Kim, Suzy, Rebecca D. Dodd, Jeffrey K. Mito, Yan Ma, Yongbaek Kim, Richard F. Riedel, and David G. Kirsch. “Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma..” Sarcoma 2012 (2012). https://doi.org/10.1155/2012/680708.
       Full Text  Link to Item
    • Riedel, Richard F., Robert G. Maki, and Andrew J. Wagner. “Targeted therapy in sarcoma: should we be lumpers or splitters?.” Am Soc Clin Oncol Educ Book, 2012, 652–57. https://doi.org/10.14694/EdBook_AM.2012.32.652.
       Full Text  Link to Item
    • Riedel, Richard F. “Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?.” Semin Oncol 38 Suppl 3 (October 2011): S30–42. https://doi.org/10.1053/j.seminoncol.2011.09.003.
       Full Text  Link to Item
    • Hsu, D. S., C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, et al. “Erratum: Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 13 (5312-5317) DOI: 10.1073/pnas.0900827106).” Proceedings of the National Academy of Sciences of the United States of America 108, no. 35 (August 30, 2011). https://doi.org/10.1073/pnas.1111196108.
       Full Text
    • Smith, Jason L., and Richard F. Riedel. “Emerging therapeutic targets for soft tissue sarcoma..” Curr Oncol Rep 13, no. 4 (August 2011): 350–58. https://doi.org/10.1007/s11912-011-0175-y.
       Full Text  Link to Item
    • Chawla, S. P., J. Blay, I. L. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, et al. “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)..” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 10005–10005. https://doi.org/10.1200/jco.2011.29.15_suppl.10005.
       Full Text
    • Chawla, S. P., J. Blay, I. L. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, et al. “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)..” J Clin Oncol 29, no. 15_suppl (May 20, 2011).
       Link to Item
    • Palta, Manisha, Richard F. Riedel, James J. Vredenburgh, Thomas J. Cummings, Scott Green, Zheng Chang, and John P. Kirkpatrick. “Primary meningeal rhabdomyosarcoma..” Sarcoma 2011 (2011). https://doi.org/10.1155/2011/312802.
       Full Text  Link to Item
    • Demetri, George D., Scott Antonia, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, Thomas F. DeLaney, et al. “Soft tissue sarcoma..” J Natl Compr Canc Netw 8, no. 6 (June 2010): 630–74. https://doi.org/10.6004/jnccn.2010.0049.
       Full Text  Link to Item
    • Demetri, George D., Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W. T. Pisters, et al. “NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors..” J Natl Compr Canc Netw 8 Suppl 2 (April 2010): S1-41. https://doi.org/10.6004/jnccn.2010.0116.
       Full Text  Link to Item
    • Mito, Jeffrey K., Richard F. Riedel, Leslie Dodd, Guy Lahat, Alexander J. Lazar, Rebecca D. Dodd, Lars Stangenberg, et al. “Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma..” Plos One 4, no. 11 (November 30, 2009). https://doi.org/10.1371/journal.pone.0008075.
       Full Text  Link to Item
    • Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors..” J Clin Oncol 27, no. 15_suppl (May 20, 2009).
       Link to Item
    • Ludwig, Corinna, Richard Riedel, Jost Schnell, and Erich Stoelben. “Inhalation with Tobramycin to improve healing of tracheobronchial reconstruction..” Eur J Cardiothorac Surg 35, no. 5 (May 2009): 797–800. https://doi.org/10.1016/j.ejcts.2008.12.048.
       Full Text  Link to Item
    • Riedel, Richard F., Nicole Larrier, Leslie Dodd, David Kirsch, Salutario Martinez, and Brian E. Brigman. “The clinical management of chondrosarcoma..” Curr Treat Options Oncol 10, no. 1–2 (April 2009): 94–106. https://doi.org/10.1007/s11864-009-0088-2.
       Full Text  Link to Item
    • Hsu, David S., Chaitanya R. Acharya, Bala S. Balakumaran, Richard F. Riedel, Mickey K. Kim, Marvaretta Stevenson, Sascha Tuchman, et al. “Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer..” Proc Natl Acad Sci U S A 106, no. 13 (March 31, 2009): 5312–17. https://doi.org/10.1073/pnas.0900827106.
       Full Text  Link to Item
    • Riedel, Richard F., Alessandro Porrello, Emily Pontzer, Emily J. Chenette, David S. Hsu, Bala Balakumaran, Anil Potti, Joseph Nevins, and Phillip G. Febbo. “A genomic approach to identify molecular pathways associated with chemotherapy resistance..” Mol Cancer Ther 7, no. 10 (October 2008): 3141–49. https://doi.org/10.1158/1535-7163.MCT-08-0642.
       Full Text  Link to Item
    • Hsu, S. D., C. R. Acharya, R. F. Riedel, R. C. Redman, K. S. Garman, H. K. Dressman, G. Ginsburg, S. Powers, D. Mu, and A. Potti. “Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2-8, and PAX9, to predict prognosis and guide therapeutic strategies..” J Clin Oncol 26, no. 15_suppl (May 20, 2008).
       Link to Item
    • Hsu, S. D., C. R. Acharya, R. F. Riedel, R. C. Redman, K. S. Garman, H. K. Dressman, G. Ginsburg, S. Powers, D. Mu, and A. Potti. “Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7511–7511. https://doi.org/10.1200/jco.2008.26.15_suppl.7511.
       Full Text
    • Riedel, R. F., D. Friedman, and P. G. Febbo. “A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma..” J Clin Oncol 26, no. 15_suppl (May 20, 2008).
       Link to Item
    • Riedel, R. F., D. Friedman, and P. G. Febbo. “A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 10577–10577. https://doi.org/10.1200/jco.2008.26.15_suppl.10577.
       Full Text
    • Hsu, David S., Bala S. Balakumaran, Chaitanya R. Acharya, Vanja Vlahovic, Kelli S. Walters, Katherine Garman, Carey Anders, et al. “Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer..” J Clin Oncol 25, no. 28 (October 1, 2007): 4350–57. https://doi.org/10.1200/JCO.2007.11.0593.
       Full Text  Link to Item
    • Riedel, Richard F., Carolyn Andrews, Jennifer Garst, Frank Dunphy, James E. Herndon, Susan Blackwell, Sally Barbour, and Jeffrey Crawford. “A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer..” J Thorac Oncol 2, no. 6 (June 2007): 520–25. https://doi.org/10.1097/JTO.0b013e318060107c.
       Full Text  Link to Item
    • Riedel, Richard F., Jeffrey Crawford, Frank Dunphy, James E. Herndon, Jennifer Garst, and Michael J. Kelley. “Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer..” Lung Cancer 54, no. 3 (December 2006): 431–32. https://doi.org/10.1016/j.lungcan.2006.08.008.
       Full Text  Link to Item
    • Riedel, Richard F., Xiaofei Wang, Meg McCormack, Eric Toloza, Gustavo S. Montana, Gilbert Schreiber, and Michael J. Kelley. “Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care..” J Thorac Oncol 1, no. 7 (September 2006): 692–96.
       Link to Item
    • Riedel, Richard F., and William R. Burfeind. “Thymoma: benign appearance, malignant potential..” Oncologist 11, no. 8 (September 2006): 887–94. https://doi.org/10.1634/theoncologist.11-8-887.
       Full Text  Link to Item
    • Riedel, Richard F., and Phillip G. Febbo. “Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer..” Future Oncol 1, no. 4 (August 2005): 461–66. https://doi.org/10.2217/14796694.1.4.461.
       Full Text  Link to Item
    • Riedel, Richard F., and Jeffrey Crawford. “Small-cell lung cancer: a review of clinical trials..” Semin Thorac Cardiovasc Surg 15, no. 4 (October 2003): 448–56.
       Link to Item
    • Luetteke, N. C., T. H. Qiu, S. E. Fenton, K. L. Troyer, R. F. Riedel, A. Chang, and D. C. Lee. “Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development..” Development 126, no. 12 (June 1999): 2739–50.
       Link to Item
    • Salomoni, P., M. A. Wasik, R. F. Riedel, K. Reiss, J. K. Choi, T. Skorski, and B. Calabretta. “Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant..” J Exp Med 187, no. 12 (June 15, 1998): 1995–2007. https://doi.org/10.1084/jem.187.12.1995.
       Full Text  Link to Item
    • Berkowitz, E. A., K. B. Seroogy, J. A. Schroeder, W. E. Russell, E. P. Evans, R. F. Riedel, H. K. Phillips, C. A. Harrison, D. C. Lee, and N. C. Luetteke. “Characterization of the mouse transforming growth factor alpha gene: its expression during eyelid development and in waved 1 tissues..” Cell Growth Differ 7, no. 9 (September 1996): 1271–82.
       Link to Item

  • Book Sections

    • Larrier, N., W. C. Eward, and R. F. Riedel. “Bone Sarcomas.” In Cancer Consult: Expertise for Clinical Practice, 687–95, 2014. https://doi.org/10.1002/9781118589199.ch105.
       Full Text

  • Other Articles

    • Potti, Anil, Holly K. Dressman, Andrea Bild, Richard F. Riedel, Gina Chan, Robyn Sayer, Janiel Cragun, et al. “Retraction: Genomic signatures to guide the use of chemotherapeutics..” Nat Med, January 2011. https://doi.org/10.1038/nm0111-135.
       Full Text  Link to Item
    • “Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–7, 2007..” J Clin Oncol, December 10, 2010. https://doi.org/10.1200/JCO.2010.33.7311.
       Full Text  Link to Item
    • Potti, A., H. K. Dressman, A. Bild, R. F. Riedel, G. Chan, R. Sayer, J. Cragun, et al. “Corrigendum: Genomic signatures to guide the use of chemotherapeutics (Nature Medicine (2006) 12, (1294-1300)).” Nature Medicine, August 1, 2008. https://doi.org/10.1038/nm0808-889.
       Full Text
    • Potti, A., H. K. Dressman, A. Bild, R. F. Riedel, G. Chan, R. Sayer, J. Cragun, et al. “Erratum: Genomic signatures to guide the use of chemotherapeutics (Nature (2006) 12, (1294-1300)).” Nature Medicine, November 1, 2007. https://doi.org/10.1038/nm1107-1388.
       Full Text
    • Potti, Anil, Holly K. Dressman, Andrea Bild, Richard F. Riedel, Gina Chan, Robyn Sayer, Janiel Cragun, et al. “Genomic signatures to guide the use of chemotherapeutics..” Nat Med, November 2006. https://doi.org/10.1038/nm1491.
       Full Text  Link to Item

  • Conference Papers

    • Gounder, Mrinal M., Neeta Somaiah, Steven Attia, Sant P. Chawla, Victor Manuel Villalobos, Bartosz Chmielowski, Melissa Amber Burgess, et al. “Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study..” In Journal of Clinical Oncology, 36:11512–11512. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.11512.
       Full Text
    • Chawla, S., B. A. Van Tine, S. Pollack, K. Ganjoo, A. Elias, R. F. Riedel, S. Attia, et al. “A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival.” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Attia, Steven, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel A. Rushing, Elizabeth Trice Loggers, et al. “A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results..” In Journal of Clinical Oncology, 35:11005–11005. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.11005.
       Full Text
    • Burgess, Melissa Amber, Vanessa Bolejack, Brian Andrew Van Tine, Scott Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, et al. “Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses..” In Journal of Clinical Oncology, 35:11008–11008. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.11008.
       Full Text
    • Burgess, Melissa Amber, Jason Roszik, Brian Andrew Van Tine, James Hu, Scott Schuetze, Sandra P. D’Angelo, Steven Attia, et al. “Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028..” In Journal of Clinical Oncology, Vol. 35. AMER SOC CLINICAL ONCOLOGY, 2017.
       Link to Item
    • Rav, Emily Miller, Richard F. Riedel, Christel N. Rushing, and Anthony N. Galanos. “Healthcare utilization among cancer patients prior to hospice.” In Journal of Clinical Oncology, Vol. 34. AMER SOC CLINICAL ONCOLOGY, 2016.
       Link to Item
    • Attia, Steven, Kamalesh Kumar Sankhala, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Patrick McKay Boland, Minal A. Barve, et al. “A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS)..” In Journal of Clinical Oncology, 34:11016–11016. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11016.
       Full Text
    • Gounder, Mrinal M., Andrew J. Wagner, Neeta Somaiah, Richard F. Riedel, Gary K. Schwartz, Steven Attia, Albiruni R. A. Razak, et al. “The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS)..” In Journal of Clinical Oncology, 34:TPS11072–TPS11072. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps11072.
       Full Text
    • Patel, Krish, Lowell T. Nicholson, and Richard F. Riedel. “Defining the characteristics of medical oncology patients requiring inpatient hospital admission..” In Journal of Clinical Oncology, 34:e18023–e18023. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e18023.
       Full Text
    • Tawbi, Hussein Abdul-Hassan, Melissa Amber Burgess, John Crowley, Brian Andrew Van Tine, James Hu, Scott Schuetze, Sandra P. D’Angelo, et al. “Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study..” In Journal of Clinical Oncology, 34:11006–11006. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11006.
       Full Text
    • Whitley, Melodi J., Diana M. Cardona, Dan G. Blazer, Shelley Hwang, Rachel A. Greenup, Paul J. Mosca, Joan Cahill, et al. “Abstract SY36-03: Intraoperative molecular imaging with protease-activated fluorescent imaging agents.” In Molecular and Cellular Biology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-sy36-03.
       Full Text
    • Attia, Steven, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Kamalesh Kumar Sankhala, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, and Robert G. Maki. “A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
       Link to Item
    • Burgess, Melissa Amber, John Crowley, Denise K. Reinke, Richard F. Riedel, Suzanne George, Sujana Movva, Brian Andrew Van Tine, et al. “SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas..” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
       Link to Item
    • Whitley, M. J., D. M. Cardona, D. G. Blazer, E. Hwang, R. A. Greenup, P. J. Mosca, J. Cahill, et al. “A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery.” In Annals of Surgical Oncology, 22:S11–12. SPRINGER, 2015.
       Link to Item
    • Whitley, Melodi Javid, Diana M. Cardona, Dan G. Blazer, Shelley E. Hwang, Paul J. Mosca, Joan Cahill, Jorge M. Ferrer, et al. “A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015..” In Journal of Clinical Oncology, 32:TPS11135–TPS11135. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps11135.
       Full Text
    • LeBlanc, Thomas William, James A. Tulsky, Amy Pickar Abernethy, Christopher A. Jones, Anthony N. Galanos, and Richard F. Riedel. “Oncologists' perceptions of rounding alongside palliative care physicians: Results of a post-intervention survey study..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Blay, Jean-Yves, Sant P. Chawla, Isabelle Ray-Coquard, Axel Le Cesne, Arthur P. Staddon, Mohammed M. Milhem, Nicolas Penel, et al. “Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results..” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
       Link to Item
    • Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Riedel, R. F., A. Porrello, E. Chenette, A. Potti, J. R. Nevins, and P. G. Febbo. “A genomic approach to identify mechanisms associated with chemotherapy resistance.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
       Link to Item
    • Riedel, R. F., P. G. Febbo, and J. Crawford. “IDENTIFYING MECHANISMS OF RESISTANCE IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING DOSE-DENSE NEOADJUVANT/INDUCTION CHEMOTHERAPY..” In Journal of Investigative Medicine, 55:S282–S282. BMJ, 2007. https://doi.org/10.1097/00042871-200701010-00730.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.